Benedict Discusses Siponimod Findings

Updated December 17, 2020

Researchers say a multiple sclerosis (MS) drug meant to slow physical disability also shows promise in improving mental acuity in people who are living with secondary progressive MS, an advanced form of the disease. “While there are currently no drugs on the market in the United States approved for the treatment of cognitive impairment in MS, our study found that siponimod, which is prescribed to slow the progression of physical disability in MS, may also help improve cognitive processing speed in people with advanced MS,” says Ralph H. Benedict, PhD, professor of neurology.